Key result
Higher baseline platelet count (> 209 × 10^9/L) was associated with a decreased risk of all-cause mortality compared to lower platelet count in patients with a history of stroke and cancer.
Why the study?
Platelet count may relate to survival in stroke and cancer, but its impact on patients with a history of both conditions is not well known.
Does a lower baseline platelet count increase the risk of all-cause mortality in patients with a history of stroke and cancer?
Cross-Sectional (n=113)
Does a lower baseline platelet count increase the risk of all-cause mortality in patients with a history of stroke and cancer?
In patients with a history of both stroke and cancer, a lower baseline platelet count (≤ 209 × 10^9/L) is an independent predictor of increased all-cause mortality.
Answers are grounded in this paper and cite their sources.
May support platelet-based risk stratification in stroke-cancer patients; hypothesis-generating, requires prospective validation.
BACKGROUND: Platelet count and function may be closely related to survival and prognosis of stroke and cancer. However, little is known on the impact of platelet count on the patients with a history of stroke and cancer. This study aimed to examine the association between baseline platelet level and all-cause mortality in this population using a cross-sectional analysis. METHODS: Participants with a history of stroke and cancer were selected from the database of the National Health and Nutrition Examination Survey from 2007 to 2018. A maximum selected rank statistic was conducted to determine platelet cutoff with the most significant association with mortality. The association between platelet and mortality was characterized visually using restricted cubic spline (RCS). Weighted multivariable Cox regression models were performed to evaluate the association between platelet count and mortality. Time-dependent receiver operating characteristic (ROC) analysis was conducted to assess the accuracy of platelet count in predicting mortality. RESULTS: /L, n = 56) (Model 1 HR 0.43, 95% CI 0.24-0.77, p = 0.005) (Model 2 HR 0.58, 95% CI 0.35-0.96, p = 0.03). Subgroup analyses showed no significant interaction between platelet and age, sex, BMI, WBC and neutrophil. The areas under time-dependent ROC curve of the 1-, 2-, 3-, 4- and 5-year survival rates were 0.54, 0.55, 0.57, 0.53, 0.59 for mortality of stroke patients with cancer. CONCLUSIONS: Lower platelet count may be an independent predictor of all-cause mortality in population with a history of stroke and cancer. This result may provide valuable insights for the long-term management in stroke patients with cancer.
No takes yet. Share an insight, caveat, or question.
Ouyang et al. (2025) conducted a cross-sectional in Stroke and cancer (n=113). Higher platelet count (> 209 × 10^9/L) vs. Lower platelet count (≤ 209 × 10^9/L) was evaluated on All-cause mortality (HR 0.43, 95% CI 0.24-0.77, p=0.005). Higher baseline platelet count (> 209 × 10^9/L) was associated with a decreased risk of all-cause mortality compared to lower platelet count in patients with a history of stroke and cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: